Vivimed Labs share news, announcements and annual reports
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.53down ₹0.11 (1.95%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹5.64.
30 Oct: open ₹5.62, high ₹5.64, low ₹5.53
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,267
Vivimed Labs share news and announcements
642 announcements, routine notices left out, newest first. Page 7 of 13.
Jun 2018
11 Jun · Corrigendum
4 Jun · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted The response of the Company is awaited.1 Jun · Analysts
May 2018
30 May · Results
Apr 2018
Mar 2018
28 Mar · Meeting
22 Mar · Board meeting
19 Mar · Board meeting
Feb 2018
14 Feb · Results
Jan 2018
Dec 2017
11 Dec · Analysts
Nov 2017
16 Nov · Analysts
14 Nov · Analysts
14 Nov · Results
3 Nov · Disclosure
Sep 2017
29 Sep · Meeting
26 Sep · Updates
1 Sep · Board meeting
Aug 2017
14 Aug · Analysts
14 Aug · Board meeting
12 Aug · Results
Jul 2017
12 Jul · Address Change
Jun 2017
22 Jun · Updates
May 2017
27 May · Results
18 May · Board meeting
Apr 2017